The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Jan. 29, 2013
Filed:
Feb. 27, 2009
Ingrid Gunda Georg, St. Paul, MN (US);
Joseph S. Tash, Leawood, KS (US);
Ramappa Chakrasali, St. Paul, MN (US);
Sudhakar Rao Jakkaraj, Falcon Heights, MN (US);
James P. Calvet, Lenexa, KS (US);
Ingrid Gunda Georg, St. Paul, MN (US);
Joseph S. Tash, Leawood, KS (US);
Ramappa Chakrasali, St. Paul, MN (US);
Sudhakar Rao Jakkaraj, Falcon Heights, MN (US);
James P. Calvet, Lenexa, KS (US);
University of Kansas, Lawrence, KS (US);
Abstract
Lonidamine derivatives can be useful in methods of treating, inhibiting, and/or preventing polycystic kidney disease (PKD). Accordingly, lonidamine derivatives can be administered in a therapeutically effective amount for inhibiting, and/or preventing polycystic kidney disease (PKD) in the subject. This can include administering a therapeutically effective amount of the lonidamine derivatives for inhibiting CFTR and/or Hsp90 or biological pathway thereof. Also, the method can include administering the lonidamine derivatives in a therapeutically effective amount for inhibiting ErbB2, Src, Raf-1, B-Raf, MEK, Cdk4, NKCC1, or combinations thereof. For example, the therapeutically effective amount of the lonidamine derivatives can be configured so as to provide a concentration in or adjacent to a kidney cell of about 0.25 uM or more or less.